The Levo System Honored as Finalist in the 2017 Medical Design Excellence Awards
Otoharmonics cited for its role as manufacturer of innovative tinnitus therapy device
PORTLAND, Ore., June 5, 2017 /PRNewswire/ -- Otoharmonics today announced that the Levo System has been selected as a finalist in the Digital Health Products and Mobile Medical Apps category of the 19th Annual Medical Design Excellence Awards competition. The 2017 winners will be announced at the 2017 MDEA Ceremony on Tuesday, June 13, 2017 in conjunction with the MD&M East event, organized by UBM, taking place at the Jacob K. Javits Convention Center in New York.
Utilizing an FDA-cleared evidence-based approach, the Levo System offers a patented method to provide personalized sound therapy while sleeping. A recently released randomized study by the National Center for Rehabilitative Auditory Research led by James Henry, PhD. at the VA Portland Health Care System demonstrated improved clinical outcomes for tinnitus patients using the Levo System.
The MDEA are the medtech industry's premier design competition committed to recognizing significant achievements in medical product design and engineering that improve the quality of healthcare delivery and accessibility. The awards program celebrates the accomplishments of the medical device manufacturers, their suppliers, and the many people behind the scenes—engineers, scientists, designers, and clinicians—who are responsible for the cutting-edge products that are saving lives; improving patient healthcare; and transforming medtech—one innovation at a time.
"On behalf of the engineers, scientists, clinicians and business professionals that contributed to the development of the Levo System, we are deeply honored to be recognized by the Medical Design Excellence Awards," said Brenda Edin, CMO of Otoharmonics. "From the start, the Levo System was developed with personalized, patient-centric design in mind."
Attendees of the MD&M East event can learn more about the development of the Levo System by attending the Case Study Presentation "The Levo System Tinnitus Therapy Device – From Sketch to Launch" on Tuesday, June 13th a 2pm in Javits Convention Center Room 1E08.
The 2017 MDEA Juror Panel selected 45 exceptional finalists in nine medical technology product categories. Products were judged based on design and engineering innovation; function and user-related innovation; patient benefits; business benefits; and overall benefit to the healthcare system. Unlike other design competitions that are merely styling contests, the MDEA jury is comprised of a balance of practicing doctors, nurses, and technicians alongside industrial designers, engineers, manufacturers, and human factors experts.
About Otoharmonics Corporation
Otoharmonics Corporation is a privately held company with headquarters in Portland, Oregon USA. An international team of world–class neuroscientists, clinicians, business professionals and patients, Otoharmonics has developed the patented Levo System for the management of tinnitus symptoms. With a personal approach and a deep understanding of the impact tinnitus can have, Levo is designed to be user-friendly and capable of delivering custom sound therapy based on the specific needs of the individual.
Otoharmonics and Levo are registered trademarks of Otoharmonics Corporation.
About Medical Design Excellence Awards
The MDEA program is presented by UBM, the global advanced manufacturing and MedTech authority, and by Medical Device and Diagnostic Industry (MD+DI), the industry's central source for late breaking news, information, and business intelligence. For more information about the Medical Design Excellence Awards—including additional details about the manufacturers and suppliers that created the 2017 MDEA-winning products—visit the MDEA website at www.MDEAwards.com or e-mail: [email protected].
Contact:
Brenda Edin
503-336-9906
[email protected]
SOURCE Otoharmonics
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article